Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23260733 | 0.92 | NR2E1 (0.42) | SLC9A1NR2E1HTR2APDE2AALDH1A1 | |
| SCHEMBL26530068 | 0.86 | NR2E1 (0.38) | SLC9A1NR2E1HTR2APDE2AALDH1A1 | |
| SCHEMBL26530058 | 0.85 | NR2E1 (0.44) | SLC9A1NR2E1HTR2APDE2AALDH1A1 | |
| SCHEMBL26530078 | 0.83 | NR2E1 (0.43) | SLC9A1NR2E1HTR2APDE2AALDH1A1 | |
| SCHEMBL26530064 | 0.81 | NR2E1 (0.43) | SLC9A1NR2E1HTR2APDE2AALDH1A1 | |
| SCHEMBL26530067 | 0.81 | RAB9A (0.52) | NR2E1HTR2AALDH1A1LMNAKDM4E | |
| SCHEMBL26535614 | 0.80 | SLC9A1 (0.45) | SLC9A1NR2E1HTR2APDE2AALDH1A1 | |
| SCHEMBL26530043 | 0.73 | PDE2A (0.41) | SLC9A1NR2E1HTR2APDE2AALDH1A1 | |
| SCHEMBL26529918 | 0.72 | NR2E1 (0.53) | SLC9A1NR2E1HTR2APDE2AALDH1A1 | |
| SCHEMBL23260468 | 0.70 | NR2E1 (0.46) | SLC9A1NR2E1HTR2APDE2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | YTHDF1, YTHDF3, YTHDF2 | SLC9A1 4843/4885NR2E1 2168/4885HTR2A 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.